Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
191
resultados
Última actualización
07/12/2025 [06:52:00]
Resultados 25 a 50 de 191
Resumen de: US2025368958A1
Chimeric antigen receptor (CAR)-expressing neutrophils loaded with nanoparticles comprising a drug; and a method of treating cancer or other disorders in a subject comprising administering to the subject a therapeutically effective amount of the CAR-expressing neutrophils.
Resumen de: WO2025250940A2
The present disclosure provides a nanobody platform having a high affinity purification on protein A, wherein the nanobodies may incorporate diverse bioactive peptides, lipid or glycoside in its CDR1 and/or CDR3 regions. The present disclosure also provides a peptide-modified nanobody comprising non-toxic bioactive peptides and that exhibit potent anti-tumor activity. Moreover, the peptide-modified nanobody is able to be combined with other technologies, such as but not limited to bispecific antibodies and antibody-drug conjugates. Further, the present disclosure also provides production processes of the nanobodies and their use as a treatment and diagnostic agents.
Resumen de: WO2025250344A1
A C-terminal fragment of insulin-like growth factor binding protein 2 (IGFBP2) containing 3 cysteine residues has been shown to spontaneously self-assemble into nanotube (NT) structures. These NTs can encapsulate drugs during the assembly process and then deliver their cargo intracellularly following binding to interns and endocytosis. The integrin-dependence of this process is mediated by the presence of a naturally occurring RGD motif within the peptide sequence. A particular advantage of such NTs is that by encapsulating small molecule drugs, tissues are protected from their adverse effects. Here, the use of NTs to deliver small drugs and biologics across the blood-brain barrier (BBB) by penetrating the CNS and delivering their cargo is described.
Resumen de: US2025367134A1
The technology includes selective modulation of only a peripheral CB1R by using a CB1R antagonist contained in a peripherally restricted delivery system.
Resumen de: WO2025250839A1
Disclosed herein are nanoparticle conjugates (e.g., anti-angiogenic and/or immunomodulatory nanoparticle conjugates, e.g., high-affinity Designed Ankyrin Repeat Protein (DARPin)-based binders targeting one or more cancer and/or immune receptors). The nanoparticle conjugates are useful for therapeutics and/or diagnostics and have a diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution).
Resumen de: WO2025250244A1
The disclosure provides particles, including anisotropic particles, and compositions, methods and kits thereof that are useful, e.g., for delivering an agent or in treating or preventing diseases, such as proliferative diseases. The disclosure also provides methods of preparing plurality of such particles and liposomes that provide control over size and morphology.
Resumen de: WO2025249682A1
The present invention relates to a cancer-targeting drug delivery system comprising: a protamine-based self-assembling first nanoparticle including a negatively charged substance; and a heparin-based self-assembling second nanoparticle including a positively charged anticancer agent and Fe3+. Specifically, the present invention provides a drug delivery system that forms aggregates at a tumor site by a guidance effect upon administration of the second nanoparticle after administration of the first nanoparticle, and has an anticancer effect through induction of ferroptosis and immunogenic cell death without exhibiting the anticoagulant effect of heparin.
Resumen de: WO2025249687A1
The present invention relates to a method for producing extracellular vesicles into which a therapeutic gene is introduced by electroporation, a wound-healing pharmaceutical composition produced by the method, and a wound-healing pharmaceutical preparation or quasi-drug preparation comprising same as an active ingredient. The extracellular vesicles derived from mesenchymal stem cells (MSCs), fibroblasts, and colostrum, produced by the present method, are all non-cytotoxic, have excellent nucleic acid delivery efficiency, and thus allow for stable expression. In particular, by introducing a vascular endothelial growth factor (VEGF) gene, which is known to have a wound-healing effect, into extracellular vesicles derived from mesenchymal stem cells (MSCs), fibroblasts, and colostrum through electroporation, VEGF gene-introduced extracellular vesicles produced by the production method of the present invention can be used as a gene therapy agent for wound healing.
Resumen de: WO2025250539A1
The present invention provides a pharmaceutical composition capable of delivering therapeutic agents such as nucleic acids to the lung via systemic administration to treat lung-related diseases. Said composition comprises a non-covalent complex formed by co-precipitating a sialic acid (SA) entity, a complexing agent, and a nucleic acid cargo.
Resumen de: WO2025248298A1
The present invention provides nano-formulation of Curcumin having nano Curcumin content up to 10% w/w in formulation (up to 90 mg) with 100% solubility in water, - and particle size less than 100 nm with good bioavailability through enhanced permeability and stability, thereby increase in their effectiveness for various therapeutic uses. The nano-formulation of Curcumin is having low particle size and increased efficacy, stability against pH, light, temperature, and humidity.
Resumen de: WO2025245652A1
Disclosed is a method for producing a hydrogel-type medical device, which comprises producing, in advance, copper nanoparticles coated with high-molecular-weight chitosan; and incorporating the particles during the final minutes of a step of crosslinking, which allows the coating to remain on the nanoparticles, preventing the dissolution thereof, and the nanoparticles to be uniformly incorporated into the latticed formation of the hydrogel. Also disclosed are the hydrogel and the use thereof in different types of wounds, burns and ulcerations.
Resumen de: WO2025245869A1
The present invention relates to an ionizable lipid molecule containing an arginine structure, lipid nanoparticles comprising same, and use thereof. Specifically, provided are an ionizable lipid molecule represented by formula (1) containing a structure of arginine and a derivative thereof, lipid nanoparticles comprising same, a preparation method therefor, and use thereof. Compared with ionizable lipid molecules conventionally used in the art, the lipid nanoparticles prepared from the ionizable lipid molecule represented by formula (1) of the present invention can achieve highly efficient delivery and expression of nucleic acids.
Resumen de: AU2024281393A1
Compositions and methods for enhancing payload-based gene therapy by increasing the percentage of payload delivered to a non-liver target in a subject by blocking binding of LDL to LDL receptors (LDLR) in the liver, and then administering a payload-based therapy targeting a non-liver tissue.
Resumen de: AU2024271802A1
The present disclosure relates generally to lipid nanoparticles (LNPs) and compositions comprising the same, and their use in delivery of agents, such as nucleic acid-based therapeutics, in particular to transfection recalcitrant cells and/or to lung tissue.
Resumen de: AU2024269259A1
In various aspects and embodiments provided are compositions containing extracellular vesicles (including modified extracellular vesicles), methods of making preparations of extracellular vesicles, methods of modifying extracellular vesicles and methods of using modified and/or unmodified extracellular vesicles.
Resumen de: AU2024251515A1
The present application relates to lipid nanoparticles containing a steroid compound, and the preparation and a use of the lipid nanoparticles. The lipid nanoparticles can be used to deliver effective loads (such as a nucleic acid) into non-liver organs such as the spleen for the treatment or prevention of certain diseases or conditions, particularly spleen-associated diseases.
Resumen de: WO2025250979A1
The disclosure relates to block copolymer nanoparticles for therapeutic delivery of nucleic acids, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering miRNAs.
Resumen de: WO2025250906A1
The present invention relates to processes for preparing lipid nanoparticles having an antibody or fragment antibody binding region.
Resumen de: WO2025250729A1
The present disclosure provides lipid compounds and compositions (e.g., lipid nanoparticle (LNP) compositions) comprising lipid compounds of the present disclosure. The present disclosure provides methods of delivering an active agent (e.g., polynucleotide) to a cell or tissue in a subject, preferably an extrahepatic cell or tissue, comprising administering to the subject an effective amount of a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises lipid compounds of the present disclosure and the active agent (e.g., polynucleotide).
Resumen de: WO2025250730A1
The present disclosure provides lipid compounds and compositions (e.g., lipid nanoparticle (LNP) compositions) comprising lipid compounds of the present disclosure. The present disclosure provides methods of delivering an active agent (e.g., polynucleotide) to a cell or tissue in a subject, preferably an extrahepatic cell or tissue, comprising administering to the subject an effective amount of a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises lipid compounds of the present disclosure and the active agent (e.g., polynucleotide).
Resumen de: WO2025248434A1
A composition for topical use in the treatment of androgenetic alopecia comprises a nanoemulsion, said nanoemulsion comprising a mixture of oils, at least one surfactant, finasteride and minoxidil. The mixture of oils comprises sandalwood oil, rosemary oil and sweet almond oil.
Resumen de: WO2025247930A1
Nanoparticles (1) for administering at least one active ingredient (4), said nanoparticles comprising a magnetizable core (2), the core (2) having a shell (3) made of a polyphosphate and said shell (3) completely enclosing the core (2), characterized in that the shell (3) is mixed with an active ingredient (4).
Resumen de: WO2025247992A1
The invention relates to antigen-functionalized dextran-based nanoparticles capable of activating, functionally modifying, re-programming, and stimulating expansion of T cells, A pharmaceutical comprising the nanoparticles find use in the treatment of a medical condition requiring the activation and/or expansion of T-cells and/or in the production of receptor engineered-T cells used in such treatments.
Resumen de: WO2025247999A1
Method for the production of extracellular vesicles, EVs, loaded with a molecule of interest in a bioreactor containing a porous three-dimensional, 3D, scaffold, wherein the method comprises a seeding of the scaffold with a starting number of adherent immortalized cells resuspended after detachment, an attachment of the cells on said scaffold, an expansion of the cells on said scaffold up to a second number of adherent cells, defining a multiplication factor of at least 5 for a single expansion step, a production of EVs by said cells, a phase of loading said EVs with said molecule of interest, a harvest of EVs.
Nº publicación: WO2025247843A1 04/12/2025
Solicitante:
INST STRAUMANN AG [CH]
INSTITUT STRAUMANN AG
Resumen de: WO2025247843A1
The present invention relates to a pharmaceutical, dental and/or cosmetic composition comprising purified and/or isolated matrix derivative (EMD) proteins and a suitable pharmaceutical carrier, characterized in that the purified and/or isolated enamel matrix derivative (EMD) proteins comprised in said composition have a predominant MW of between 10-13kDa and an aggregation particle size of between 20-200 nm at Room Temperature (RT) and a pH of between 60-7.5. Said pharmaceutical, dental and/or cosmetic composition is disclosed for use in healing, restoration, enhancement and/or promotion of soft tissue in the oral cavity and/or craniomaxillofacial complex (CMF), in particular for use in treating patients suffering from a gingival deficiency and/or disorder. Preferably, the composition of the invention is administered via injection into the soft tissue in the oral cavity and/or the craniomaxillofacial complex (CMF) of the patient.
BOPI
Sede Electrónica
